OBI Pharma Inc (台灣浩鼎) shares yesterday rose 2.29 percent following a two-day slump, after the biotech firm cleared up rumors of irregularities in the provision of stock compensation to interested parties.
Shares of OBI Pharma closed at NT$670 in Taipei trading, following declines of 2.51 percent and 6.43 percent in the past two sessions.
The company dismissed rumors that it had granted shares to Academia Sinica president Wong Chi-huey (翁啟惠), who later transferred the shares to company chairman Michael Chang (張念慈).
Academia Sinica, the nation’s leading research academy, works in close collaboration with OBI Pharma.
OBI Pharma was founded by Chang and Wong as a wholly owned subsidiary of US-based Optimer Pharmaceuticals Inc in April of 2012. Optimer Pharmaceuticals ousted Chang, who had served as chairman at OBI Pharma, on suspicion that Chang had arranged for a grant of 1.5 million OBI Pharma shares to himself for the benefit of a third party.
OBI Pharma said that throughout the company’s history, it has never approved share grants for members of its research team, management or interested parties.
In addition, the company said that Wong was not involved in Optimer Pharmaceutical’s October 2012 decision to sell the remaining stakes of its former subsidiary back to OBI Pharma shareholders and that Chang was later cleared of wrongdoing following probes by US financial regulators.
Chang had no control on prices in the selling of shares, which was initiated by Optimer to raise funds, OBI Pharma said, adding that the rumors are aimed at stirring controversy over the ownership of the company’s OBI-822 medicine, a promising active immunotherapy for metastatic breast cancer, after its share prices soared, while vowing to take legal action over unfounded rumors.
OBI Pharma last month announced that it has inked an agreement to transfer exclusive rights for Merck & Co Inc of the US to develop and commercialize the company’s narrow spectrum antibiotic Dificid in Taiwan.
Dificid has been approved by Taiwanese authorities to treat closridium difficile-related diarrhea in adults.
In related news, TaiGen Biotechnology Co (太景生技) shares yesterday gained 7.71 percent to climb to NT$37 after the company announced that its pneumonia drug Taigexyn is going through phase-three clinical trials and that a new drug application would be submitted to the Chinese Food and Drug Administration next year.
The news came after TaiGen said last week it had received approval from the Chinese agency for the phase-two clinical trial of Burixafor, an autologous hematopoietic stem-cell transplantation drug.
So far this year, TaiGen shares have dropped 4.27 percent on the Taipei Exchange, outperforming the over-the-counter benchmark index, which has dropped 6.35 percent over the same period.
Polytronics Technology Corp (聚鼎科技) yesterday announced that it is buying Henkel AG’s thermal clad dielectric material (TCLAD) business division for US$26 million as the Taiwanese firm aims to improve its technology, product portfolio and revenue performance. Polytronics, headquartered in the Hsinchu Science Park (新竹科學園區), is a supplier of protection components and heat dissipation materials. The firm entered the metallic heat-dissipation substrate market in 2007 and developed a unique solventless production process. Its board of directors approved signing an agreement with Henkel to acquire the German chemical firm’s TCLAD division in the US. The purchase includes all assets and business interests, including equipment,
SIZE MATTERS: Medium-sized hotels that do not have the support of parent groups are more vulnerable and are forced to take action, a REPro Knight Frank researcher said About 50 hotels across Taiwan are seeking to exit the market as they succumb to the bleak business outlook amid international travel restrictions imposed to combat the COVID-19 pandemic. Yomi Hotel (優美飯店) on Minsheng E Road, Sec 1, in Taipei is seeking to transfer ownership with an asking price of NT$950 million (US$32.15 million) and a pledge for a lease contract that guarantees a 3 percent return. The budget hotel, with room rates that start from NT$1,400 per night, maintains normal operations, but has been struggling since March, when the government placed restrictions on inbound and outbound travel. Occupancy rates for hotels in
With the US dollar expected to weaken in the next 12 months due to near-zero interest rates, investors should consider purchasing US corporate bonds, Standard Chartered Bank Taiwan Ltd (渣打台灣銀行) said on Thursday. The bank said that the US Federal Reserve since last month has been buying bonds issued by US companies to curb default rates. The US dollar is forecast to be weaker against the pound, the euro and the yen, as well as the Canadian dollar, the Swedish krona and the Swiss franc, as the greenback lacks high investment returns after the Fed in March slashed the benchmark interest rate
A Bollywood actor’s face tattooed on his arm, Sandeep Bacche’s devotion shocks few in India where stars enjoy semi-divine status, but even there the hallowed silver screen might be losing its shine to streaming services and pandemic fears. “Whenever things get better and theaters begin operations, I will watch three movies a day for sure just as a way to celebrate,” said the Mumbai rickshaw driver, who is recovering from the virus himself. However, others might not join the party. With cinemas shut for months due to a COVID-19 lockdown, and little prospect they will reopen soon, frustrated Bollywood producers have turned to